GB0128138D0 - Pharmaceutical use - Google Patents

Pharmaceutical use

Info

Publication number
GB0128138D0
GB0128138D0 GBGB0128138.5A GB0128138A GB0128138D0 GB 0128138 D0 GB0128138 D0 GB 0128138D0 GB 0128138 A GB0128138 A GB 0128138A GB 0128138 D0 GB0128138 D0 GB 0128138D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical use
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0128138.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Priority to GBGB0128138.5A priority Critical patent/GB0128138D0/en
Publication of GB0128138D0 publication Critical patent/GB0128138D0/en
Priority to PCT/GB2002/005300 priority patent/WO2003045430A1/en
Priority to AU2002343085A priority patent/AU2002343085A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0128138.5A 2001-11-23 2001-11-23 Pharmaceutical use Ceased GB0128138D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0128138.5A GB0128138D0 (en) 2001-11-23 2001-11-23 Pharmaceutical use
PCT/GB2002/005300 WO2003045430A1 (en) 2001-11-23 2002-11-25 Tnf-alpha inhibitors for the treatment of hepatic diseases
AU2002343085A AU2002343085A1 (en) 2001-11-23 2002-11-25 Tnf-alpha inhibitors for the treatment of hepatic diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0128138.5A GB0128138D0 (en) 2001-11-23 2001-11-23 Pharmaceutical use

Publications (1)

Publication Number Publication Date
GB0128138D0 true GB0128138D0 (en) 2002-01-16

Family

ID=9926358

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0128138.5A Ceased GB0128138D0 (en) 2001-11-23 2001-11-23 Pharmaceutical use

Country Status (3)

Country Link
AU (1) AU2002343085A1 (en)
GB (1) GB0128138D0 (en)
WO (1) WO2003045430A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
CA2566975A1 (en) * 2004-06-04 2005-12-15 Apoxis Sa Method to reduce hepatotoxicity of fas-mediated apoptosis-inducing agents

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US6107273A (en) * 1995-01-24 2000-08-22 Thomas Jefferson University Tumor necrosis factor inhibitors
US5753628A (en) * 1995-06-07 1998-05-19 Centocor, Inc. Peptide inhibitors of TNF containing predominantly D-amino acids
AU4959997A (en) * 1996-11-15 1998-06-10 Kennedy Institute Of Rheumatology, The Suppression of tnf alpha and il-12 in therapy
AU8747998A (en) * 1997-08-21 1999-03-16 Takeda Chemical Industries Ltd. Anti-inflammatory agent
EP1029851B1 (en) * 1997-10-14 2005-04-20 Mitsubishi Pharma Corporation Piperazine compounds and medicinal use thereof
JPH11127882A (en) * 1997-10-27 1999-05-18 Nippon Kayaku Co Ltd Novel physiologically active substance nk30424a and nk3024 b, their production and use
JPH11228576A (en) * 1997-12-10 1999-08-24 Japan Tobacco Inc Apoptosis inhibitor
FR2779724B1 (en) * 1998-06-10 2001-04-20 Rhone Poulenc Rorer Sa PYRROLE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2000062790A2 (en) * 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
JP2001081088A (en) * 1999-09-10 2001-03-27 Nippon Kayaku Co Ltd New physiologically active substance nk3042 analogue and production and use thereof

Also Published As

Publication number Publication date
WO2003045430A1 (en) 2003-06-05
AU2002343085A1 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
HUP0302857A3 (en) Pharmaceutical formulation
GB0104534D0 (en) Pharmaceutical combination
GB0118689D0 (en) Pharmaceutical formulation
PL366510A1 (en) Pharmaceutical combinations
PL366432A1 (en) Pharmaceutical formulation
GB0101227D0 (en) Pharmaceutical compounds
GB0101225D0 (en) Pharmaceutical compounds
GB0124523D0 (en) Pharmaceutical combination
GB0129270D0 (en) Pharmaceutical combination
GB0129397D0 (en) Pharmaceutical combination
GB0129872D0 (en) Novel pharmaceutical
GB0129395D0 (en) Pharmaceutical combination
GB0128138D0 (en) Pharmaceutical use
GB0130511D0 (en) Novel pharmaceutical
GB0130510D0 (en) Novel pharmaceutical
GB0130509D0 (en) Novel pharmaceutical
GB0129876D0 (en) Novel pharmaceutical
GB0104749D0 (en) Pharmaceutical formulation
GB0127358D0 (en) Pharmaceutical use
GB0129871D0 (en) Novel pharmaceutical
GB0117778D0 (en) New pharmaceutical use
GB0129396D0 (en) Pharmaceutical combination
GB0129275D0 (en) Pharmaceutical combination
GB0110575D0 (en) Pharmaceutical combinations
GB0129849D0 (en) Novel pharmaceutical

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)